AstraZeneca’s mRNA-Based AZD8601 Succeeds At Phase II, Propelling Moderna Into Heart Space

 
• By Ayisha Sharma

AstraZeneca and Moderna’s mRNA-based candidate AZD8601 has shown promise in a small Phase II heart study, strengthening the latter’s foray into the cardiovascular arena and beyond its vaccine niche.    

Moderna's mRNA Technology Seems Applicable Outside Of Infectious Diseases • Source: Alamy

More from Clinical Trials

More from R&D